表柔比星,奥沙利铂和卡培他滨二线方案治疗晚期胃癌的疗效

[目的]探讨表柔比星,奥沙利铂和卡培他滨二线方案治疗晚期胃癌的临床疗效及毒副作用.[方法]对本院收治的80例胃腺癌患者在一线方案治疗后效果不佳且病情进展时给予二线方案治疗,根据患者用药方式的不同分为A组与B组,A组给予表柔比星+奥沙利铂+卡培他滨(mEXO)治疗,B组给予伊立替康+氟尿嘧啶+亚叶酸钙(FOLFIRI)治疗,比较两组患者疗效以及化疗后产生的毒副作用情况.[结果]A组治疗后疾病控制率达42.5％(17/40),B组疾病控制率达47.5％(19/40),两组相比较差异无显著性(P＞0.05);但B组患者血液毒性反应、腹泻与外周神经毒性反应Ⅰ～Ⅱ度发生率显著高于A组,且差异有显著性(P＜0.05).[结论]晚期胃癌患者经一线化疗效果不佳后,若患者还能承受二线化疗,可采用表柔比星,奥沙利铂联合卡培他滨方案化疗,且效果确切,且毒副作用较小,值得临床治疗借鉴.

Clinical Efficacy and Side effects of Epirubicin,Oxaliplatin and Capecitabine in the Treatment of Advanced Gastric Cancer

[Objective]To investigate the clinical efficacy and side effects of epirubicin,oxaliplatin and capecitabine in the treatment of advanced gastric cancer.[Methods]Eighty cases of patients with gastric cancer treated in our hospital after first-line treatment with poor results and progressive disease were given with second-line treatment.The patients were divided into group A and group B according to the different methods of medication,the Group A was given epirubicin-+-oxaliplatin + capecitabine (mEXO) treatment,the group B was given irinotecan -+-5-fluorouracil-+-leucovorin (FOLFIRI) treatment,the efficacy and toxicity of two groups were compared.[Resuits]The disease control rate was 42.5％ (17/40) in the Group A,and that of the control group was 47.5％(19/40),there was no significant difference between the two groups (P ＞0.05);However,the incidence of blood toxicity,diarrhea and Ⅰ ～ Ⅱ peripheral neurotoxicity in patients of the Group B were significantly higher than those in the Group A,and the difference was statistically significant (P ＜0.05).[Conclusion]If the they can withstand,patients with advanced gastric cancer may use epirubicin,oxaliplatin combined with capecitabine as secondline chemotherapy after the firskline chemotherapy proves to be ineffective.The effect is exact,the side effect is small,and is worthy of clinical treatment.